Previous 10 |
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced t...
Summary Halvorsen's 13F portfolio value decreased from $24.74B to $21.86B this quarter. The number of positions increased from 56 to 82. Viking Global added McKesson, American International Group, and Intuit while decreasing T-Mobile US, General Electric, and Brookfield Asset Mana...
PepGen press release ( NASDAQ: PEPG ): Q2 GAAP EPS of -$1.23 misses by $0.47 . Cash and cash equivalents were $218.8 million For further details see: PepGen GAAP EPS of -$1.23 misses by $0.47
BOSTON, Aug. 12, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported fin...
BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a Boston-based clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today...
PepGen press release (NASDAQ:PEPG): Q1 GAAP EPS of -$18.94. Cash and cash equivalents were $118.9 million as of March 31, 2022, which excludes the proceeds from our IPO in May 2022. For further details see: PepGen GAAP EPS of -$18.94
BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported fin...
News, Short Squeeze, Breakout and More Instantly...
2024-07-06 15:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointments of...
Michelle Mellion, M.D., promoted to Chief Medical Officer Hayley Parker, Ph.D., promoted to Senior Vice President, Global Regulatory Affairs PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of t...